ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ziltivekimab

Also written as “Ziltivekimab”, “Ziltivekimab B” and “Ziltivekimab C”.

Its studies are mostly in Renal Insufficiency, Chronic · Heart Failure · Myocardial Infarction · Coronary Artery Disease · Anemia, led by 2 companies.

Drug pageZiltivekimab: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 19, 202112 company-led studies, 4 open or runningNext primary completion: Jan 29, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only113 open or runningphase 3since Aug 19, 2021Mar 19, 2012Jan 29, 2027phase 3 · NCT06118281
ECRI bv11 open or runningphase 3since Nov 28, 2025Nov 28, 2025Sep 1, 2028phase 3 · NCT07276282
  • Named in Novo Nordisk’s own pipeline as Ziltivekimab, phase 3, as of Nov 5, 2026 (source).

Also a collaborator on its studies: Corvidia Therapeutics and Cardialysis.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ECRI bv only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2019Named ziltivekimabINNProposed as its International Nonproprietary Name in WHO's List 121 · before, COR-001, MEDI5117
  2. Nov 28, 2025First study: phase 3 study in Coronary Artery DiseaseFirst studyNCT07276282 · 332 planned · Switzerland

Ahead

  1. Sep 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseNCT07276282

TargetBeta

IL6 →read by rule
“Interleukin-6 inhibitor; Interleukin-6 binding agent”ChEMBL 37, by rule

Other programs on IL6

ProgramCompanyFurthest phaseStudies
olokizumabruleR-Pharmphase 319
clazakizumabCSLphase 310
pacibekitugruleNovartisphase 31
isomyosamineruletnf-pharmaceuticals-incphase 21

Studies

The one study ECRI bv leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07276282Coronary Artery Disease · Switzerland3RecruitingSep 1, 2028332

How it is read

Names in the registry

  • “Ziltivekimab”, 8 entries
  • “Ziltivekimab B”, 2 entries
  • “Ziltivekimab C”, 2 entries
  • “COR-001”, 1 entry
  • “MEDI5117”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.